Skip to main content Accessibility help
×
Home

High-through identification of T cell-specific phage-exposed mimotopes using PBMCs from tegumentary leishmaniasis patients and their use as vaccine candidates against Leishmania amazonensis infection

  • Gerusa B. Carvalho (a1), Lourena E. Costa (a1), Daniela P. Lage (a1), Fernanda F. Ramos (a1), Thaís T. O. Santos (a1), Patrícia A. F. Ribeiro (a1), Daniel S. Dias (a1), Beatriz C. S. Salles (a1), Mariana P. Lima (a1), Lívia M. Carvalho (a2), Ana C. S. Dias (a3), Patrícia T. Alves (a3), Michelle L. Franklin (a1), Renata A. M. Silva (a1), Mariana C. Duarte (a1) (a4), Daniel Menezes-Souza (a1) (a4), Bruno M. Roatt (a2), Miguel A. Chávez-Fumagalli (a1), Luiz Ricardo Goulart (a3) (a5), Antonio L. Teixeira (a1) (a6) (a7) and Eduardo A. F. Coelho (a1) (a4)...

Abstract

In the current study, phage-exposed mimotopes as targets against tegumentary leishmaniasis (TL) were selected by means of bio-panning cycles employing sera of TL patients and healthy subjects, besides the immune stimulation of peripheral blood mononuclear cells (PBMCs) collected from untreated and treated TL patients and healthy subjects. The clones were evaluated regarding their specific interferon-γ (IFN-γ) and interleukin-4 (IL-4) production in the in vitro cultures, and selectivity and specificity values were calculated, and those presenting the best results were selected for the in vivo experiments. Two clones, namely A4 and A8, were identified and used in immunization protocols from BALB/c mice to protect against Leishmania amazonensis infection. Results showed a polarized Th1 response generated after vaccination, being based on significantly higher levels of IFN-γ, IL-2, IL-12, tumour necrosis factor-α (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF); which were associated with lower production of specific IL-4, IL-10 and immunoglobulin G1 (IgG1) antibodies. Vaccinated mice presented significant reductions in the parasite load in the infected tissue and distinct organs, when compared with controls. In conclusion, we presented a strategy to identify new mimotopes able to induce Th1 response in PBMCs from TL patients and healthy subjects, and that were successfully used to protect against L. amazonensis infection.

Copyright

Corresponding author

Author for correspondence: Eduardo A. F. Coelho, E-mail: eduardoferrazcoelho@yahoo.com.br

Footnotes

Hide All
*

Co-senior authors.

Footnotes

References

Hide All
Aghebati-Maleki, L, Bakhshinejad, B, Baradaran, B, Motallebnezhad, M, Aghebati-Maleki, A, Nickho, H, Yousefi, M and Majidi, J (2016) Phage display as a promising approach for vaccine development. Journal of Biomedical Science 23, 66.
Alban, SM, Moura, JF, Thomaz-Soccol, V, Bührer Sékula, S, Alvarenga, LM, Mira, MT, Olortegui, CC and Minozzo, JC (2014) Phage display and synthetic peptides as promising biotechnological tools for the serological diagnosis of leprosy. PLoS One 9, e106222.
Alves, PT, Fujimura, PT, Morais, LD and Goulart, LR (2014) Revisiting the CD14: epitope mapping by phage display. Immunobiology 219, 822829.
Amit, A, Vijayamahantesh, , Dikhit, MR, Singh, AK, Kumar, V, Suman, SS, Singh, A, Kumar, A, Thakur, AK, Das, VR, Das, P and Bimal, S (2017) Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in BALB/c mice. Molecular Immunology 82, 104113.
Arakaki, TL, Buckner, FS, Gillespie, JR, Malmquist, NA, Phillips, MA, Kalyuzhniy, O, Luft, JR, Detitta, GT, Verlinde, CL, Van Voorhis, WC, Hol, WG and Merritt, EA (2008) Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Molecular Microbiology 68, 3750.
Atanackovic, D, Altorki, NK, Stockert, E, Williamson, B, Jungbluth, AA, Ritter, E, Santiago, D, Ferrara, CA, Matsuo, M, Selvakumar, A, Dupont, B, Chen, YT, Hoffman, EW, Ritter, G, Old, LJ and Gnjatic, S (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. The Journal of Immunology 172, 32893296.
Bayih, AG, Daifalla, NS and Gedamu, L (2017) Immune response and protective efficacy of a heterologous DNA-protein immunization with Leishmania superoxide dismutase B1. Biomed Research International 2017, 2145386.
Bezerra, IPS, Amaral Abib, M and Rossi-Bergmann, B (2018) Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis. Vaccine 36, 24802486.
Campos, BL, Silva, TN, Ribeiro, SP, Carvalho, KI, Kallás, EG, Laurenti, MD and Passero, LF (2015) Analysis of iron superoxide dismutase-encoding DNA vaccine on the evolution of the Leishmania amazonensis experimental infection. Parasite Immunology 37, 407416.
Cano, PG, Gamage, LNA, Marciniuk, K, Hayes, C, Napper, S, Hayes, S and Griebel, PJ (2017) Lambda display phage as a mucosal vaccine delivery vehicle for peptide antigens. Vaccine 35, 72567263.
Coelho, EAF, Tavares, CA, Carvalho, FA, Chaves, KF, Teixeira, KN, Rodrigues, RC, Charest, H, Matlashewski, G, Gazzinelli, RT and Fernandes, AP (2003) Immune responses induced by the Leishmania (leishmania) donovani a2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (leishmania) amazonensis infection. Infection and Immunity 71, 39883994.
Coelho, EA, Chávez-Fumagalli, MA, Costa, LE, Tavares, CA, Soto, M and Goulart, LR (2015) Theranostic applications of phage display to control leishmaniasis: selection of biomarkers for serodiagnostics, vaccination, and immunotherapy. Revista da Sociedade Brasileira de Medicina Tropical 48, 370379.
Cordeiro, AT, Feliciano, PR, Pinheiro, MP and Nonato, MC (2012) Crystal structure of dihydroorotate dehydrogenase from Leishmania major. Biochimie 94, 17391748.
Costa, LE, Lima, MIS, Chávez-Fumagalli, MA, Menezes-Souza, D, Martins, VT, Duarte, MC, Lage, OS, Lopes, EGP, Lage, DP, Ribeiro, TG, Andrade, PHR, Magalhães-Soares, DF, Soto, M, Tavares, CAP, Goulart, LR and Coelho, EAF (2013) Subtractive phage display selection from canine visceral leishmaniasis identifies novel epitopes that mimic Leishmania infantum antigens with potential serodiagnosis applications. Clinical and Vaccine Immunology 21, 111.
Costa, LE, Chávez-Fumagalli, MA, Martins, VT, Duarte, MC, Lage, DP, Lima, MI, Pereira, NC, Soto, M, Tavares, CA, Goulart, LR and Coelho, EA (2015) Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection. Parasitology 42, 13351347.
Costa, LE, Salles, BCS, Santos, TTO, Ramos, FF, Lima, MP, Lima, MIS, Ásb, P, Chávez-Fumagalli, MA, Duarte, MC, Menezes-Souza, D, Machado-de-Ávila, RA, Silveira, JAG, Magalhães-Soares, DF, Goulart, LR and Coelho, EAF (2017) Antigenicity of phage clones and their synthetic peptides for the serodiagnosis of canine and human visceral leishmaniasis. Microbial Pathogenesis 110, 1422.
Deak, E, Jayakumar, A, Cho, KW, Goldsmith-Pestana, K, Dondji, B, Lambris, JD and McMahon-Pratt, D (2010) Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. European Journal of Immunology 40, 13551368.
DebRoy, S, Prosper, O, Mishoe, A and Mubayi, A (2017) Challenges in modeling complexity of neglected tropical diseases: a review of dynamics of visceral leishmaniasis in resource limited settings. Emerging Themes in Epidemiology 14, 10.
Dias, DS, Martins, VT, Ribeiro, PAF, Ramos, FF, Lage, DP, Tavares, GSV, Mendonça, DVC, Chávez-Fumagalli, MA, Oliveira, JS, Silva, ES, Gomes, DA, Rodrigues, MA, Duarte, MC, Galdino, AS, Menezes-Souza, D and Coelho, EAF (2017) Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis. Parasitology 8, 112.
Dias, DS, Ribeiro, PAF, Martins, VT, Lage, DP, Costa, LE, Chávez-Fumagalli, MA, Ramos, FF, Santos, TTO, Ludolf, F, Oliveira, JS, Mendes, TAO, Silva, ES, Galdino, AS, Duarte, MC, Roatt, BM, Menezes-Souza, D, Teixeira, AL and Coelho, EAF (2018) Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis. Translational Research. doi: 10.1016/j.trsl.2018.05.001.
Duarte, MC, Lage, DP, Martins, VT, Chávez-Fumagalli, MA, Roatt, BM, Menezes-Souza, D, Goulart, LR, Soto, M, Tavares, CA and Coelho, EA (2016) Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical 49, 398407.
Duarte, MC, Lage, DP, Martins, VT, Costa, LE, Carvalho, AMRS, Ludolf, F, Santos, TTO, Vale, DL, Roatt, BM, Menezes-Souza, D, Fernandes, AP, Tavares, CAP and Coelho, EAF (2017) A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection. Immunobiology 222, 251260.
Feliciano, ND, Ribeiro Vda, S, Santos Fde, A, Fujimura, PT, Gonzaga, HT, Goulart, LR and Costa-Cruz, JM (2014) Bacteriophage-fused peptides for serodiagnosis of human strongyloidiasis. PLoS Neglected Tropical Diseases 8, e2792.
Garde, E, Ramírez, L, Corvo, L, Solana, JC, Martín, ME, González, VM, Gómez-Nieto, C, Barral, A, Barral-Netto, M, Requena, JM, Iborra, S and Soto, M (2018) Analysis of the antigenic and prophylactic properties of the Leishmania translation initiation factors eIF2 and eIF2b in natural and experimental leishmaniasis. Frontiers in Cellular and Infection Microbiology 8, 112.
Gerlach, JT, Ulsenheimer, A, Grüner, NH, Jung, MC, Schraut, W, Schirren, CA, Heeg, M, Scholz, S, Witter, K, Zahn, R, Vogler, A, Zachoval, R, Pape, GR and Diepolder, HM (2005) Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. The Journal of Virology 79, 1242512433.
Goulart, LR, Vieira, CU, Freschi, AP, Capparelli, FE, Fujimura, PT, Almeida, JF, Ferreira, LF, Goulart, IM, Brito-Madurro, AG and Madurro, JM (2010) Biomarkers for serum diagnosis of infectious diseases and their potential application in novel sensor platforms. Critical Reviews in Immunology 30, 201222.
Goulart, LR, Ribeiro, SV and Costa-Cruz, JM (2017) Anti-parasitic antibodies from phage display. Advances in Experimental Medicine and Biology 1053, 155171.
Hernández-Ruiz, J and Becker, I (2006) CD8+ cytotoxic lymphocytes in cutaneous leishmaniasis. Salud Publica de México 48, 430439.
Hirve, S, Kroeger, A, Matlashewski, G, Mondal, D, Banjara, MR, Das, P, Be-Nazir, A, Arana, B and Olliaro, P (2017) Towards elimination of visceral leishmaniasis in the Indian subcontinent-translating research to practice to public health. PLoS Neglected Tropical Diseases 11, e0005889.
Honoré, S, Garin, YJ, Sulahian, A, Gangneux, JP and Derouin, F (1998) Influence of the host and parasite strain in a mouse model of visceral Leishmania infantum infection. FEMS Immunology and Medical Microbiology 21, 231239.
Husmann, LA and Bevan, MJ (1988) Cooperation between helper T cells and cytotoxic T lymphocyte precursors. Annals of the New York Academy of Sciences 532, 158.
Inaoka, DK, Sakamoto, K, Shimizu, H, Shiba, T, Kurisu, G, Nara, T, Aoki, T, Kita, K and Harada, S (2008) Structures of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with substrates and products: atomic resolution insights into mechanisms of dihydroorotate oxidation and fumarate reduction. Biochemistry 47, 1088110891.
Keene, and Forman, J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. The Journal of Experimental Medicine 155, 768.
Kuhn, P, Fühner, V, Unkauf, T, Moreira, GM, Frenzel, A, Miethe, S and Hust, M (2016) Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. Proteomics Clinical Applications 10, 922948.
Lage, DP, Martins, VT, Duarte, MC, Garde, E, Chávez-Fumagalli, MA, Menezes-Souza, D, Roatt, BM, Tavares, CA, Soto, M and Coelho, EA (2015) Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis. Parasite Immunology 37, 646656.
Lima, MP, Costa, LE, Duarte, MC, Menezes-Souza, D, Salles, BCS, Santos, TTO, Ramos, FF, Chávez-Fumagalli, MA, Kursancew, ACS, Ambrosio, RP, Roatt, BM, Machado-de-Avila, RA, Goncalves, DU and Coelho, EAF (2017) Evaluation of a hypothetical protein for serodiagnosis and as a potential marker for post-treatment serological evaluation of tegumentary leishmaniasis patients. Parasitology Research 117, 18.
Link, JS, Alban, SM, Soccol, CR, Pereira, GV and Soccol, VT (2017) Synthetic peptides as potential antigens for cutaneous leishmaniosis diagnosis. Journal of Immunological Research 2017, 5871043.
Lipford, GB, Bauer, M, Blank, C, Reiter, R, Wagner, H and Heeg, K (1997) CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. European Journal of Immunology 27, 23402344.
Manoutcharian, K (2005) Bacteriophages as tools for vaccine and drug development. Expert Review of Vaccines 4, 57.
Margaroni, M, Agallou, M, Athanasiou, E, Kammona, O, Kiparissides, C, Gaitanaki, C and Karagouni, E (2017) Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmaniaantigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis. The International Journal of Nanomedicine 12, 61696184.
Martins, VT, Duarte, MC, Chávez-Fumagalli, MA, Menezes-Souza, D, Coelho, CS, de Magalhães-Soares, DF, Fernandes, AP, Soto, M, Tavares, CA and Coelho, EA (2015) A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis. Parasites & Vectors 8, 363.
Martins, VT, Duarte, MC, Lage, DP, Costa, LE, Carvalho, AM, Mendes, TA, Roatt, BM, Menezes-Souza, D, Soto, M and Coelho, EA (2017 a) A recombinant chimeric protein composed of human and mice-specific CD4+ and CD8+ T-cell epitopes protects against visceral leishmaniasis. Parasite Immunology 39, e12359.
Martins, VT, Lage, DP, Duarte, MC, Carvalho, AM, Costa, LE, Mendes, TA, Vale, DL, Menezes-Souza, D, Roatt, BM, Tavares, CA, Soto, M and Coelho, EA (2017 b) A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection. Cellular Immunology 313, 3242.
Mendonça, DVC, Martins, VT, Lage, DP, Dias, DS, Ribeiro, PAF, Carvalho, AMRS, Dias, ALT, Miyazaki, CK, Menezes-Souza, D, Roatt, BM, Tavares, CAP, Barichello, JM, Duarte, MC and Coelho, EAF (2018) Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. Experimental Parasitology 186, 2435.
Mohsen, MO, Gomes, AC, Cabral-Miranda, G, Krueger, CC, Leoratti, FM, Stein, JV and Bachmann, MF (2017) Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. The Journal of Controlled Release 251, 92100.
Oliveira, MP, Martins, VT, Santos, TTO, Lage, DP, Ramos, FF, Salles, BCS, Costa, LE, Dias, DS, Ribeiro, PAF, Schneider, MS, Machado-de-Ávila, RA, Teixeira, AL, Coelho, EAF and Chávez-Fumagalli, MA (2018) Small myristoylated protein-3, identified as a potential virulence factor in Leishmania amazonensis, proves to be a protective antigen against visceral leishmaniasis. International Journal of Molecular Sciences 19, 1.
Oyarzun, P and Kobe, B (2015) Computer-aided design of T-cell epitope-based vaccines: addressing population coverage. The International Journal of Immunogenetics 42, 313321.
Pinheiro, MP, Iulek, J and Nonato, MC (2008) Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase from Y strain. Biochemical and Biophysical Research Communications 369, 812817.
Pinheiro, MP, Emery, FS and Nonato, MC (2013) Target sites for the design of anti-trypanosomatid drugs based on the structure of dihydroorotate dehydrogenase. Current Pharmaceutical Design 19, 26152627.
Poland, GA, Ovsyannikova, IG, Jacobson, RM and Smith, DI (2007) Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clinical Pharmacology & Therapeutics 82, 653664.
Ponte-Sucre, A, Gamarro, F, Dujardin, JC, Barrett, MP, López-Vélez, R, García-Hernández, R, Pountain, AW, Mwenechanya, R and Papadopoulou, B (2017) Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Neglected Tropical Diseases 11, e0006052.
Pratti, JE, Ramos, TD, Pereira, JC, Fonseca-Martins, AM, Maciel-Oliveira, D, Oliveira-Silva, G, Mello, MF, Chaves, SP, Gomes, DC, Diaz, BL, Rossi-Bergmann, B and Guedes, HLM (2016) Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57BL/6 mice. Parasites & Vectors 9, 534.
Ramírez, L, Corvo, L, Duarte, MC, Chávez-Fumagalli, MA, Valadares, DG, Santos, DM, de Oliveira, CI, Escutia, MR, Alonso, C, Bonay, P, Tavares, CA, Coelho, EA and Soto, M (2014) Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis. Parasites & Vectors 7, 3.
Ramos, FF, Costa, LE, Dias, DS, Santos, TTO, Rodrigues, MR, Lage, DP, Salles, BCS, Martins, VT, Ribeiro, PAF, Chávez-Fumagalli, MA, Dias, ACS, Alves, PT, Vieira, ELM, Roatt, BM, Menezes-Souza, D, Duarte, MC, Teixeira, AL, Goulart, LR and Coelho, EAF (2017) Selection strategy of phage-displayed immunogens based on an in vitro evaluation of the Th1 response of PBMCs and their potential use as a vaccine against Leishmania infantum infection. Parasites & Vectors 10, 617.
Reed, SG, Coler, RN, Mondal, D, Kamhawi, S and Valenzuela, JG (2016) Leishmania vaccine development: exploiting the host-vector-parasite interface. Expert Review of Vaccines 15, 8190.
Ribeiro, JG, Ferreira, AS, Macedo, SRA, Rossi, NRDLP, da Silva, MCP, Guerra, RNM, de Barros, NB and Nicolete, R (2017) Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania(l.) amazonensis in experimental cutaneous leishmaniasis model. International Immunopharmacology 47, 227230.
Roman, M, Martin-Orozco, E, Goodman, JS, Nguyen, M-D, Sato, Y, Ronaghy, A, Kornbluth, RS, Richman, DD, Carson, DA and Raz, E (1997) Immunostimulatory DNA sequences function as Th1 promoting adjuvants. Nature Medicine 3, 849854.
Saldarriaga, OA, Travi, BL, Park, W, Perez, LE and Melby, PC (2006) Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 24, 19281940.
Sanchez, MV, Eliçabe, RJ, Di Genaro, MS, Germanó, MJ, Gea, S, García Bustos, MF, Salomón, MC, Scodeller, EA and Cargnelutti, DE (2017) Total Leishmania antigens with poly(I:C) induce Th1 protective response. Parasite Immunology 39, 11.
Santos, TTO, Martins, VT, Lage, DP, Costa, LE, Salles, BCS, Carvalho, AMRS, Dias, DS, Ribeiro, PAF, Chávez-Fumagalli, MA, Machado-de-Ávila, RA, Roatt, BM, de Magalhães-Soares, DF, Menezes-Souza, D, Coelho, EAF and Duarte, MC (2017) Probing the efficacy of a heterologous Leishmania/l. Viannia braziliensis recombinant enolase as a candidate vaccine to restrict the development of L. infantum in BALB/c mice. Acta Tropica 171, 816.
Schieferdecker, A, Oberle, A, Thiele, B, Hofmann, F, Göthel, M, Miethe, S, Hust, M, Braig, F, Voigt, M, von Pein, UM, Koch-Nolte, F, Haag, F, Alawi, M, Indenbirken, D, Grundhoff, A, Bokemeyer, C, Bacher, U, Kröger, N and Binder, M (2016) A transplant ‘immunome’ screening platform defines a targetable epitope fingerprint of multiple myeloma. Blood 127, 32023214.
Singh, B and Sundar, S (2012) Leishmaniasis: vaccine candidates and perspectives. Vaccine 30, 38343842.
Singh, OP, Hasker, E, Sacks, D, Boelaert, M and Sundar, S (2014) Asymptomatic Leishmania infection: a new challenge for Leishmania control. Clinical and Infectious Diseases 58, 14241429.
Somers, VA, Brandwijk, RJ, Joosten, B, Moerkerk, PT, Arends, JW, Menheere, P, Pieterse, WO, Claessen, A, Scheper, RJ, Hoogenboom, HR and Hufton, SE (2002) A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. The Journal of Immunology 169, 27722780.
Sundar, S and Chakravarty, J (2013) Leishmaniasis: an update of current pharmacotherapy. Expert Opinion on Pharmacotherapy 14, 5363.
Sundar, S and Singh, A (2016) Recent developments and future prospects in the treatment of visceral leishmaniasis. Therapeutic Advances in Infectious Disease 3, 98109.
Toledo-Machado, CM, Bueno, LL, Menezes-Souza, D, Machado-de-Avila, RA, Nguyen, C, Granier, C, Bartholomeu, DC, Chávez-Olórtegui, C and Fujiwara, RT (2015) Use of phage display technology in development of canine visceral leishmaniasis vaccine using synthetic peptide trapped in sphingomyelin/cholesterol liposomes. Parasites & Vectors 8, 133.
Velez, ID, Gilchrist, K, Arbelaez, MP, Rojas, CA, Puerta, JA, Antunes, CM, Zicker, F and Modabber, F (2005) Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Transactions of the Royal Society of Tropical Medicine and Hygiene 99, 593598.
Vyas, VK and Ghate, M (2011) Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Review in Medicinal Chemistry 11, 10391055.
Wanasen, N, Xin, L and Soong, L (2008) Pathogenic role of B cells and antibodies in murine Leishmania amazonensis infection. International Journal for Parasitology 38, 417429.
Wang, R, Chen, L and Cotter, RJ (1990) Effects of peptide hydrophobicity and charge state on molecular ion yields in plasma desorption mass spectrometry. Analytical Chemistry 62, 17001705.
World Health Organization (2010) Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. World Health Organization Tech Rep Ser 949. Geneva: WHO.

Keywords

Type Description Title
WORD
Supplementary materials

Carvalho et al. supplementary material
Figures S1-S2

 Word (968 KB)
968 KB

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed